Usana Health Sciences
USNA
182 hedge funds and large institutions have $758M invested in Usana Health Sciences in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 65 increasing their positions, 68 reducing their positions, and 16 closing their positions.
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
2% more funds holding
Funds holding: 179 → 182 (+3)
0.27% more ownership
Funds ownership: 54.21% → 54.48% (+0.27%)
4% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 68
9% less capital invested
Capital invested by funds: $832M → $758M (-$73.9M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$4.79M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.88M |
| 3 |
CEI
Clark Estates Inc
New York
|
+$3.46M |
| 4 |
BlackRock
New York
|
+$3.31M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.13M |
Top Sellers
USNA Hedge Fund Activity: Q2 2022 in Review
182 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Usana Health Sciences (USNA) for Q2 2022, worth a combined $758M — down 8.9% from $832M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new USNA positions and 16 closed out — a net gain of 6 holders — while 65 added to existing stakes and 68 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.79M. The largest seller was Wellington Management Group, exiting entirely with an estimated $7.49M sold.
- 182 institutional investors held Usana Health Sciences (USNA) as of Q2 2022, up from 179 in Q1 2022.
- Funds reported $758M of Usana Health Sciences stock for Q2 2022, down 8.9% quarter-over-quarter.
- 22 funds opened new Usana Health Sciences positions in Q2 2022 and 16 closed out, a net change of +6 holders.
- The largest Usana Health Sciences buyer in Q2 2022 was Morgan Stanley, an estimated $4.79M added.
- The largest Usana Health Sciences seller in Q2 2022 was Wellington Management Group, an estimated $7.49M sold.
Based on aggregated 13F filings for Q2 2022.